Here's a roundup of climax developments at the biotech space at the last 24 hours:
Scaling The Peaks
Fight the virus----Via great hospital equiment(We provide medical service and ultrasonic parts to hospital/Clinic)
(Biotech Stocks Hitting 52-week Highs June 25)
Down at The Dumps
(Biotech Stocks Hitting 52-week Lows June 25)
Stocks at concentrate ZoGEnix Seizure remedy Approved With REMS Restriction
ZoGEnix, Inc. (NASDAQ: ZGNX) said the FDA has approved its Fintepla oral solution, CIV, because the treatment of seizures associated with Dravet syndrome at patients 2 and older. The company said the remedy will exist launched over a restricted distribution program, the FINTEPLA danger Evaluation and Mitigation tactic Program, and is expected ought exist available over its specialty pharmacy fellow by the purpose of July.
The stock was rallying by 16.54% ought $32.77 premarket Friday.
MediciNova Announces magazine Of definite Preclinical news because MN-166 at Glioblastoma
MediciNova, Inc. (NASDAQ: MNOV), which recently announced a European enthusiastic ought award patent, announced definite preclinical findings published at Frontiers at Immunology regarding the outlook of MN-166 because an adjunct treatment because glioblastoma.
In premarket trading, the stock was higher by 13.07% at $6.40.
Altimmune Shares obtain at Fund Buying
Altimmune Inc (NASDAQ: ALT) shares rose after Venrock Healthcare Partners II disclosed at a SEC filing a 20.8% stake at Altimmune as of June 15.
The stock was up 24.05% at $11.40 premarket.
See also: The Week Ahead at Biotech: Karyopharm, ZoGEnix, Heron, Chiasma at The Radar Ahead Of FDA Decisions
AbbVie's Allergan Unit GEts finish Response alphabet because Eye Disorder Drug
ABBV) Allergan unit and and Molecular Partners said the FDA has issued a finish Response alphabet ought the BLA because Abicipar pegol, an investigational DARPin therapy because patients with neovascular aGE-related macular deGEneration." data-reactid="67">AbbVie Inc's (NYSE: ABBV) Allergan unit and and Molecular Partners said the FDA has issued a finish Response alphabet ought the BLA because Abicipar pegol, an investigational DARPin therapy because patients with neovascular aGE-related macular deGEneration.
The FDA said the worth of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 mL results at an unfavorable benefit-risk, prompting the CRL. AbbVie said it plans ought encounter with the FDA ought conflict its comments and decide next steps.
In premarket trading Friday, AbbVie shares were adding 0.52% ought $97.49.
DBV Announces charge Cuts, Including Workforce Reduction
The FDA has yet ought decide at the BLA from DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) because its peanut allergy leather patch. The company said it is initiating a global and comprehensive restructuring project that includes a important reduction at workforce.
The company said it is contemplating charge reduction measures over the organization while preserving heart activities and competencies.
DBV said it now expects its rest of money and money equivalents of 262.4 million euros ($294.2 million) at the purpose of the first quarter of 2020 will exist sufficient ought fund operations significantly beyond the foregoing guidance of the first quarter of 2021.
The stock was sliding 15% ought $4.59 at premarket trading Friday.
Keros ought note Russell 2000 Index
Keros said it is put ought note the Russell 2000 Index effective after the near of the U.S. markets June 26.
Axsome GEts Breakthrough Therapy Designation because AXS-05
AXSM) said the FDA has granted Breakthrough Therapy designation because AXS-05 because the treatment of Alzheimer's illness agitation." data-reactid="78">Axsome Therapeutics Inc (NASDAQ: AXSM) said the FDA has granted Breakthrough Therapy designation because AXS-05 because the treatment of Alzheimer's illness agitation.
In premarket trading Friday, the stock was adding 9.61% ought $83.97.
Offerings
Milestone Scientific Inc. (NYSE: MLSS) priced its underwritten offering of 6.52 million shares of its mutual stock and warrants ought buy up ought an aggregate of 3.26 million shares of its mutual stock.
Each fraction of mutual stock is being sold toGEther with a justify ought buy 0.5 of a fraction at a combined charge of $2.15. The company expects ought originate sum proceeds of $14 million from the offering. The offering is expected ought near at or nearly June 30.
The stock was down 18.37% ought $2 premarket Friday.
Medical appliance maker Soliton Inc. (NASDAQ: SOLY) announced that it intends ought propose shares of its mutual stock at an underwritten public offering.
In premarket trading Friday, the stock was plunging 16.03% ought $9.95.
On The Radar PDUFA Dates
CHMA) NDA because Mycapssa, which is being evaluated because a maintenance therapy because acromegaly." data-reactid="87">The FDA is also expected ought control at Chiasma Inc's (NASDAQ: CHMA) NDA because Mycapssa, which is being evaluated because a maintenance therapy because acromegaly.
Heron Therapeutics Inc (NASDAQ: HRTX) is awaiting an FDA nod because its HTX-011 because a treatment option because post-operative pain.
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has a PDUFA engagement of June 26 because the NDA because its NASH remedy candidate obeticholic acid. With an Adcom assembly originally scheduled because June 9 having been postponed, it is less apt that an approval will come through.
IPOs
Fusion Pharmaceuticals. a clinical-staGE oncology company focused at developing next-GEneration radiopharmaceuticals because precision medicines, priced its initial public offering of 12.5 million shares at $17 per share, at the estimated charge ranGE of $14-$16. The shares are ought exist listed at the Nasdaq beneath the ticker token "FUSN."
Akouos, Inc., which is developing GEne therapies with the latent ought restore, improve, and reserve high-acuity physiologic hearing because nation who alive with disabling hearing loss, priced its IPO of 12.5 million shares at $17 per share. The shares will exist listed at the Nasdaq beneath the ticker token "AKUS."
PolyPid Ltd, a phase 3 clinical-staGE pharmaceutical company focused at developing tarGEted, locally administered and prolonGEd-release therapeutics using its proprietary PLEX technology, priced its IPO of 3.75 million shares at $16 per fraction compared ought the estimated charge ranGE of $15-$17. The shares will begin trading at the Nasdaq beneath the ticker token "PYPD."
Related Link: Evoke GEts FDA Nod because Gimoti, A Nasally-Administered Gastroparesis remedy
See more from Benzinga
© 2020 Benzinga.com. Benzinga does no equip investment advice. sum rights reserved.
Hitachi Aloka HI VISION PREIRUS: Image Interference
GE VIVID I system maintainance
